scioDiscover - Drug Target Discovery

 

You identified a compound with the desired effect ?

 

You are looking for its target(s) ?

Which additional pathways are affected ?

Which proteins are altered in a diseased tissue ?

 

Get the whole picture of protein expression in multiple pathways !

 

 

 

Profound knowledge about protein expression levels is of utmost importance for the discovery and evaluation of new drug targets. Our Scio-Discover Service is fully immuno-based and covers proteins involved in major disease and signalling pathways as well as secreted proteins. For the highly-parallel protein analysis only minimal amounts of sample are required. No sample fractionation or depletion is needed. Our platform is able to process most biological samples without the need for laborious sample preparation, saving time and resources.

 

Applications:

  • Drug Target Identification and verification studies
  • Mechanistic studies for various indications
  • Correlate Next-Gen-Sequencing Data to protein expression levels
  • Profile cytokine and inflammatory status of your samples

 

Key advantages:

  • Low sample consumption 
  • Investigation of human and murine samples*
  • Fast turnaround time, as low as two weeks**
  • No need for laborious depletion or fractionation of your samples
  • High sensitivity (as sensitive as an ELISA or better)
  • High reproducibility (CV < 10%)
  • Various sample types can be investigated
    • Serum / Plasma
    • Tissue
    • Cell culture
    • Cerebrospinal fluid (CSF)

 

Service Features:

  • Study Layout
  • Protein Extraction and Purification
  • Protein Quantification
  • Protein labelling with high-performance fluorescent dyes
  • Automated array incubation and handling 
  • Array scanning and data acquisition
  • Data analysis according to your requirements
  • Individual study report

 

Overview
Scio-Discover
    Array
Content
    Biomarker
Discovery
    Contact
us

 

 

* other species on request

** depending on study design and sample numbers

 

 

Do you like to subscribe our newsletter ?      Yes   No

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1030 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels Tyrosine,…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Ubiquitination…
scioCyto

scioCyto

Cytokine profiling scioCyto is a high-content analysis service for cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell cultur supernatants…

News

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Macrophage-derived IL-1β and TNF-α regulate arginine metabolism in neuroblastoma

| Decembre 2018 | Study by our collaborator Dr Francis Mussai at University of Birmingham suggests arginine metabolism as a target for neuroblastoma therapy. At Sciomics we are proud of having contributed to this exciting study by a scioDiscover protein profiling study. The article is published in Cancer Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

New article | Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells

| January 2018 | A scioDiscover protein microarray study contributed to an article in Cell Reports. In this study Gerard Ruiz-Babot et al. analysed a donor specific reprogramming of cells.

Customer testimonial Leonardo Guasti, PhD (senior author):

This has undoubtedly opened new avenues in our research. We have found the Sciomics team to be extremely helpful and efficient during the whole process, from advising the best strategy to the final interpretation of results.

> More testimonials

A glas full of hope | Ein Glas Hoffnung

| January 2018 | Article on the StartUp Sciomics and our antibody microarray platform by our partner SCHOTT nexterion.

> English version "A glass full of hope"

> Deutsche Version "Ein Glas Hoffnung"

Tweets

  • 10 days ago

    RT @MCDS_Therapy: Fantastic news - we are now halfway to reaching our recruitment target in the UK! 🙌 Recruitment will continue at our two…

  • 13 days ago

    RT @MCDS_Therapy: Huge congratulations to the @AKUSociety on the positive outcomes of their #DrugRepurposing clinical trial 👏 We are using…

  • 16 days ago

    RT @MCDS_Therapy: Recruitment into our #ClinicalTrial is coming along nicely and we have now got 5 participants registered in the UK! 🙌 R…

  • 19 days ago

    RT @BioRNCluster: 🗣️#BioRNMember @sciomics has two open positions: one lab technician and one team assistant. Spread the word! Sciomics - E…

  • 29 days ago

    RT @MCDS_Therapy: #DrugRepurposing is significantly faster and cheaper than conventional drug discovery. This is why we are using it in our…